Skip Navigation
  Search Menu
Find an Expert

 

Michael Mingzhao Xing, M.D., Ph.D.

Photo of Dr. Michael Mingzhao Xing, M.D., Ph.D.

Professor of Medicine

Male

Languages: English, Chinese

Expertise: Endocrine Diseases, Endocrinology, Hyperthyroidism, Hypothyroidism, Thyroid Cancer, Thyroid Diseases, Thyroid Nodules

Research Interests: Thyroid Cancer; Thyroid Nodules

Request an Appointment

I live in Maryland

410-955-9270
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Outpatient Center
Appointment Phone: 410-955-9270

601 N. Caroline St.
Baltimore, MD 21287 map
Phone: 410-502-6888
Fax: 410-367-2042

The Johns Hopkins Hospital
Appointment Phone: 410-955-9270

600 N. Wolfe Street
Sheikh Zayed Tower Suite 333
Baltimore, MD 21287 map
Phone: 410-502-6888
Fax: 410-367-2042

Background

Michael Mingzhao Xing, M.D., Ph.D., is tenured Professor of Medicine, Oncology, Pathology, and Cellular & Molecular Medicine, Director of the Thyroid Tumor Center, and Chief of the Laboratory for Cellular and Molecular Thyroid Research at the Johns Hopkins University School of Medicine.

He previously received medical training at the Second Military Medical University in Shanghai, China and Ph D training at Case Western Reserve University in Cleveland, Ohio, USA. He received medical residency training at Greater Baltimore Medical Center and clinical endocrinology fellowship training at Johns Hopkins Hospital in Baltimore, Maryland, USA. American board-certified in Internal Medicine and Endocrinology & Metabolism, for the last 16 years, Dr. Xing has been working at Johns Hopkins Hospital as an endocrine subspecialty consultant and teaching attending while directing a thyroid research program as a physician scientist there.

His main clinical and research interests are in thyroid diseases, particularly thyroid tumor. Supported by the American Cancer Society and NIH R0-1 grants, his laboratory has been studying molecular, genetic, and epigenetic mechanisms of thyroid cancer and their clinical translation.

He has 150 publications in various prestigious journals, such as JCEM, Clinical Cancer Research, Cancer Research, Journal of Clinical Investigation, JNCI, Journal of Clinical Oncology, JAMA Oncology, Lancet, JAMA, Nature Reviews Cancer, and Endocrine Reviews.

He holds/co-holds six USA patents on such thyroid research contributions as initial discovery and clinical characterization of the BRAF V600E and TERT promoter mutations in thyroid cancer and initial demonstration of targeting BRAF/MEK to restore thyroid gene expression and radioiodine uptake for radioiodine treatment of thyroid cancer.  His work is consistently among world's top 1% citations in the thyroid field (received 11,000 citations) in recent years, which brought him the 2006 Maryland Innovator Award, the 2013 British Endocrine Society's Endocrine-Related Cancer Research Award, the 2014 Chinese Endocrine Society's Zhu Xianyi (朱宪彝) Award, and the 2016 American Thyroid Association's Paul Starr Award. He has been recognized among the "World's Top 10 Thyroid Cancer Experts" by Expertscape and "America's Top Doctors" by US News & World Reports and other professional recognition entities.

He has served several leadership roles at the American Thyroid Association, including the Research Committee Chair, Associate Editor of the journal Thyroid, and Co-Chair of the 2016-2017 ATA Annual Meeting Program Committee.

...read more

Titles

  • Professor of Medicine
  • Professor of Oncology
  • Professor of Pathology

Education

Degrees

  • MD, Second Military Medical University (1984)

Residencies

  • Greater Baltimore Medical Center / Internal Medicine (2000)

Fellowships

  • University of California San Diego School of Medicine / Pharmacology (1997)
  • Johns Hopkins University School of Medicine / Endocrinology and Metabolism (2003)

Board Certifications

  • American Board of Internal Medicine / Endocrinology/Diabetes/Metabolism (2003)
  • American Board of Internal Medicine / Internal Medicine (2000)

Research & Publications

Clinical Trial Keywords

Thyroid Cancer, novel therapeutic agents, diagnostic and prognostic molecular markers

Selected Publications

Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD. "Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244." J Clin Endocrinol Metab. 2007 Dec;92(12):4712-8. Epub 2007 Sep 18.

Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M. "Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer." Int J Cancer. 2006 Nov 15;119(10):2322-9.

Hu S, Ewertz M, Tufano RP, Brait M, Carvalho AL, Liu D, Tufaro AP, Basaria S, Cooper DS, Sidransky D, Ladenson PW, Xing M. "Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer." J Clin Endocrinol Metab. 2006 Jan;91(1):98-104. Epub 2005 Nov 1.

Is this you? Edit Profile